Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535766 · ClinicalTrials.gov registry record
An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions
A clinical trial of Lung Cancer, sponsored by St Elizabeth Healthcare.
- Completed
- Registry status
- 2,100
- Enrollment target
- 1
- Study location
NCT03535766: Completed study of Lung Cancer, sponsored by St Elizabeth Healthcare.
NCT03535766 is a study of Lung Cancer that has completed, run by St Elizabeth Healthcare. The registered enrollment target is 2,100 participants, above the 931-participant average among 409 other Lung Cancer trials with a reported enrollment target (126% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03535766, a study of Lung Cancer, has completed, sponsored by St Elizabeth Healthcare.
- COMPLETED
- Registry status
- 2,100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, minimal risk, physician initiated retrospective chart review. An analysis of treatment timelines for patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion. The study investigator and designee(s) will review patient electronic medical records, extracting data related to the symptom presentation, diagnosis, and treatment of new diagnoses of lung cancer. Collected data will focus on dates of encounters, diagnostic imaging/procedures, and treatments, with data analysis evaluating time between care encounters and potential delays in care. The data will be further stratified based on system-wide changes implemented to improve efficiency, patient outcomes, and patient experience.
Primary Outcome
Time from initial patient presentation with symptoms or incidental finding to first day of treatment, measured in days.
Conditions Studied
Study Locations (1)
Kentucky
- St. Elizabeth Healthcare - Edgewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-01-09 |
What the finished NCT03535766 record still lists
NCT03535766 is an observational study that tracks outcomes without assigning an intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 931-participant average among 409 other Lung Cancer trials with a reported enrollment target (126% higher).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03535766 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT03535766 about?
NCT03535766 is a clinical study titled "An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions". This study is a single center, minimal risk, physician initiated retrospective chart review. An analysis of treatment timelines for patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion. The study investigator and designee(s) will review patient...
What is the current status of trial NCT03535766?
This trial is currently completed. The enrollment target is 2,100 participants. The study started on 2018-03-01. Estimated completion is 2023-01-09.
What conditions does trial NCT03535766 study?
This clinical trial studies the following conditions: Lung Cancer.
Who is sponsoring clinical trial NCT03535766?
This trial is sponsored by St Elizabeth Healthcare, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03535766 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03535766's enrollment target sits among peer trials
2,100 27th of 409 higher than 383 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI